Search academic texts

Information × Registration Number 0223U003276, 0121U112070 , R & D reports Title Analysis of the course and complications of pharmacotherapy of ankylosing spondylitis and systemic lupus erythematosus depending on treatment programs popup.stage_title Head Kovalenko Volodymyr Mykolaiovych, Доктор медичних наук Registration Date 12-04-2023 Organization State Institution "National Scientific Center "Institute of Cardiology named after academician M.D. Strazhesko" of the National Academy of Medical Sciences of Ukraine popup.description2 The object of the study: patients with ankylosing spondylitis (AS), systemic lupus erythematosus (SLE). The purpose: to conduct an analysis of various treatment programs for AS and SLE based on a comprehensive study of the clinical features of the disease course and laboratory markers of inflammatory process activity, to substantiate new approaches of differentiated treatment taking into account the complications of pharmacotherapy. Research methods: clinical (complaints, anamnesis, physical examination methods, BASDAI, BASFI, BASMI indices), questionnaires (Medical Outcomes Study-Short Form-36 questionnaire), retrospective analysis of medical documentation (analysis of laboratory and radiological studies), statistical (processing of results using programs Microsoft Excel 2013, “Statistica 10.0 portable”). It was established that a decrease in bone mineral density (BMD) and osteoproliferative changes have common risk factors: the activity and duration of AS, smoking and the use of glucocorticoids, and the age of a patient with AS does not belong to the risk factors of a decrease in BMD and the development of syndesmophytes. It has also been proven that in the case of central AS, extending the interval between injections of Infliximab biosimilar up to 10 weeks in the second year of treatment does not lead to negative consequences, while in peripheral AS it is associated with an increase in the severity of symptoms. When studying patients with SLE, it was established that the period of verification of the diagnosis was 1.94 years on average, which is compatible to international data, however, it is reliably more prolonged in patients older than 40 years, as well as in the presence of a dominant joint syndrome at the onset. Among the synthetic antirheumatic drugs, mycophenolate mofetil has shown the best efficacy and safety profile in SLE, so it is the drug of choice in patients with lupus nephritis, as well as with a heavy comorbid background. Product Description popup.authors Biliavska Iuliia V. Bortkevych Oleh P. Havrylenko Tetiana I. Garmish Olena O. Dubas Vitalli V. Kovalenko Volodymyr M. Kovalenko Serhii O. Lichman OIeksander M. Levchenko Volodymyr H. Pidhaina Olena A. Pasternak Marta L. Protsenko Halyna O. Romanovsky Andrii V. Sytenko Anastasiia O. Talayeva Tetyana V. popup.nrat_date 2023-04-12 Close